Caroline M. Tanner

EPIDEMIOLOGY OF PARKINSON'S DISEASE

Samuel M. Goldman, C. Tanner, S. Goldman, 1996, Neurologic Clinics.

Benefits and Risks of Pharmacological Treatments for Essential Tremor

William G. Ondo, Stanley Fahn, Rajesh Pahwa, 2003, Drug safety.

The role of environmental toxins in the etiology of Parkinson's disease

C. Tanner, Caroline M. Tanner, 1989, Trends in Neurosciences.

Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort

Norbert Schuff, Arthur W. Toga, John Seibyl, 2018, Movement disorders : official journal of the Movement Disorder Society.

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa

Anthony E. Lang, Stanley Fahn, David Oakes, 1996 .

Lessons Learned From Past Gene-Environment Interaction Successes

Peter Kraft, Kimberly McAllister, Nilanjan Chatterjee, 2017, American journal of epidemiology.

CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study

Arthur W. Toga, Leslie M. Shaw, John Q. Trojanowski, 2016, Acta Neuropathologica.

The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort

Norbert Schuff, Arthur W. Toga, John Seibyl, 2018, Annals of clinical and translational neurology.

Web-Based Genome-Wide Association Study Identifies Two Novel Loci and a Substantial Genetic Component for Parkinson's Disease

Nicholas Eriksson, Samuel M. Goldman, Chuong B. Do, 2011, PLoS genetics.

Movement Disorder Society Unified Parkinson Disease Rating Scale experiences in daily living: Longitudinal changes and correlation with other assessments

Anthony E. Lang, David Oakes, Bernard Ravina, 2013, Movement disorders : official journal of the Movement Disorder Society.